Atara Biotherapeutics is a clinical-stage T-cell immunotherapy company leveraging an allogeneic Epstein-Barr virus (EBV) T-cell platform. Its lead product, tab-cel (Ebvallo/tabelecleucel), is approved in the EU, UK, and Switzerland for EBV+ post-transplant lymphoproliferative disease (EBV+ PTLD) and under BLA review in the U.S. The company partners with Pierre Fabre for global commercialization. Its pipeline included ATA3219 and ATA3431 (allogeneic CAR T programs), both paused in March 2025.
Q2 FY2026 — expected 2026-09-09
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-16 | 2025-12-31 | 0001193125-26-108361 | EDGAR | 106K words |
| 2025-03-07 | 2024-12-31 | 0000950170-25-035507 | EDGAR | 107K words |
| 2024-03-28 | 2023-12-31 | 0000950170-24-037644 | EDGAR | 104K words |
| 2023-02-08 | 2022-12-31 | 0000950170-23-002185 | EDGAR | 102K words |
| 2022-02-28 | 2021-12-31 | 0001564590-22-007633 | EDGAR | — |
| 2021-03-01 | 2020-12-31 | 0001564590-21-009854 | EDGAR | — |
| 2020-02-27 | 2019-12-31 | 0001564590-20-007027 | EDGAR | — |
| 2019-02-26 | 2018-12-31 | 0001564590-19-004275 | EDGAR | — |
| 2018-02-27 | 2017-12-31 | 0001564590-18-003390 | EDGAR | — |
| 2017-03-09 | 2016-12-31 | 0001564590-17-003792 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-08-12 | 2026-06-30 | 0001193125-26-346885 | EDGAR | 69K words |
| 2025-11-12 | 2025-09-30 | 0001193125-25-276219 | EDGAR | 71K words |
| 2025-08-11 | 2025-06-30 | 0000950170-25-106550 | EDGAR | 69K words |
| 2025-05-15 | 2025-03-31 | 0000950170-25-072040 | EDGAR | 68K words |
| 2024-11-12 | 2024-09-30 | 0000950170-24-125389 | EDGAR | 68K words |
| 2024-08-12 | 2024-06-30 | 0000950170-24-095533 | EDGAR | 66K words |
| 2024-05-09 | 2024-03-31 | 0000950170-24-056959 | EDGAR | 65K words |
| 2023-11-01 | 2023-09-30 | 0000950170-23-057147 | EDGAR | 66K words |
| 2023-08-08 | 2023-06-30 | 0000950170-23-039820 | EDGAR | 64K words |
| 2023-05-08 | 2023-03-31 | 0000950170-23-018820 | EDGAR | 61K words |
| 2022-11-08 | 2022-09-30 | 0000950170-22-023248 | EDGAR | — |
| 2022-08-08 | 2022-06-30 | 0000950170-22-015536 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-08-12 | 0001193125-26-346857 | EDGAR | 3K words |
| 2026-03-16 | 0001193125-26-108344 | EDGAR | 2K words |
| 2026-03-12 | 0001193125-26-103127 | EDGAR | 1K words |
| 2026-03-03 | 0001193125-26-086793 | EDGAR | 1K words |
| 2026-02-23 | 0001193125-26-062534 | EDGAR | 1K words |
| 2026-01-12 | 0001193125-26-010342 | EDGAR | 1K words |
| 2026-01-02 | 0001193125-26-000907 | EDGAR | 1K words |
| 2025-11-12 | 0001193125-25-276209 | EDGAR | 3K words |
| 2025-10-07 | 0001193125-25-232117 | EDGAR | 1K words |
| 2025-09-04 | 0000950170-25-112898 | EDGAR | 1K words |
218 total filings indexed. 186 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001604464 |
| Ticker | ATRA |
| Exchange | Nasdaq |
| SIC | 2836: Biological Products, (No Diagnostic Substances) |
| Incorporated | DE |
| Website | https://www.atarabio.com |
| Listed | 2014-10-16 |
This is a static snapshot. For live, structured JSON with cryptographic provenance chain:
MCP (recommended for AI): claude mcp add origin --transport http https://origin.rootz.global/mcp
Try it — paste this into your AI:
Works in ChatGPT, Claude, Gemini, or any AI. Free, structured, cryptographically signed — ~500 tokens vs 130,000 scraping an IR site.
claude mcp add origin --transport http https://origin.rootz.global/mcpGET https://origin.rootz.global/api/company/ATRA (~200 tokens, structured JSON with cryptographic provenance)